


Hepatitis C: State of Medicaid Access Report Card

Puerto Rico



Grade	Recommendations to Improve Patient Access
C	<ul style="list-style-type: none"> Remove prior authorization for HCV treatment. Remove certification requirement for primary care providers. Remove additional restrictions as described below.

State Overview

As of August 2021, 1,500,000 individuals were enrolled in Medicaid and CHIP. The Puerto Rico Department of Health is a single state agency, which has a cooperative agreement with the *Administración de Seguros Salud de Puerto Rico (ASES)*,¹ called *El Plan de Salud VITAL* (VITAL Health Plan). ASES implements and administers the island-wide health insurance system and contracts with four managed care organizations (MCOs): First Medical Health Plan, MMM Multi Health, Plan de Salud Menonita, and Triple-S Salud.²

Mavyret is the preferred regimen for Puerto Rico’s Medicaid program.³

Deductions		Policy
Prior Authorization	-8	Prior authorization is required for preferred HCV treatment regimens. ⁴
Fibrosis Restrictions	0	Puerto Rico Medicaid does not impose fibrosis restrictions. ⁵
Substance Use Restrictions	0	Puerto Rico Medicaid does not impose substance use restrictions. ⁶
Prescriber Restrictions	-8	Puerto Rico Medicaid imposes prescriber restrictions. Treatment must be prescribed by an Infectious Disease Specialist, Hepatologist, Gastroenterologist, Liver Transplant Specialist, Renal Transplant Specialist, or an HIV Specialist. ⁷ Primary Care Physicians certified by the Empire Liver Foundation or another comparable entity can prescribe treatment to non-complicated patients. ⁸
Retreatment Restrictions	0	Puerto Rico Medicaid does not appear to impose retreatment restrictions. ⁹
Access in Managed Care	0	First Medical Health Plan, MMM Multi Health, Plan de Salud Menonita, and Triple-S Salud impose the same requirements as FFS. ¹⁰
Additional Restrictions	-8	Puerto Rico Medicaid imposes additional restrictions as follows: ¹¹ <ul style="list-style-type: none"> Laboratory testing for “serum bilirubin levels, ALT levels, albumin levels, and INR” with results no more than 30 days prior to the submission of the prior authorization request. Documentation of genotype. Required adherence tracking during treatment. “No additional supply of the medication will be authorized when the patient claims that it was lost, stolen, or missing.”
Total Deductions	-24	Total Score [100-Deductions] 76
		Grade C

Contact Your State Officials

Medicaid Office¹²: Dinorah Collazo, Executive Director, Departamento de Salud Programa Medicaid
 Departamento de Salud, P.O. Box 70184, San Juan, PR 00936-8184, Telephone: (787)-765-2929; Email Address: prmedicaid@salud.pr.gov

Key Sources¹³

Clinical Criteria: [Administración de Seguros Salud de Puerto Rico, Glecaprevir and Pibrentasvir \(Mavyret\) Clinical Criteria](#)

Prior Authorization: [Administración de Seguros Salud de Puerto Rico, Glecaprevir and Pibrentasvir \(Mavyret\) PA Form](#)

¹ Centers for Medicare & Medicaid Services, Quality of Care in Puerto Rico: <https://perma.cc/8TZQ-MKTN>.

² Managed Care in Puerto Rico, <https://perma.cc/9X98-BH4V>.

³ Clinical Criteria.

⁴ Clinical Criteria.

⁵ Clinical Criteria.

⁶ Clinical Criteria.

⁷ Clinical Criteria.

⁸ Clinical Criteria.

⁹ Clinical Criteria.

¹⁰ Clinical Criteria.

¹¹ Clinical Criteria.

¹² Department of Health PR, Contact Us: <https://perma.cc/TYE5-MZ2D>.

¹³ The clinical criteria and prior authorization forms may be accessed from the following landing page: Puerto Rico Health Insurance Administration, Protocolos Clínicos de Medicamentos (accessed Feb. 10, 2023), <https://perma.cc/5CJH-DP4A>.